Intersect ENT (NASDAQ:XENT) announced its quarterly earnings results on Thursday. The medical equipment provider reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02), Bloomberg Earnings reports. Intersect ENT had a negative net margin of 24.99% and a negative return on equity of 22.90%. The business had revenue of $26.66 million during the quarter, compared to analyst estimates of $27.13 million. During the same quarter last year, the company posted ($0.14) earnings per share. The company’s revenue was up 1.4% compared to the same quarter last year. Intersect ENT updated its FY 2019 guidance to EPS.
XENT opened at $20.13 on Friday. Intersect ENT has a twelve month low of $19.48 and a twelve month high of $35.87. The business’s fifty day moving average price is $21.71. The firm has a market capitalization of $628.36 million, a PE ratio of -26.49 and a beta of 0.80.
In other Intersect ENT news, insider Susan P. Stimson sold 5,350 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $27.38, for a total value of $146,483.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Lisa D. Earnhardt sold 9,500 shares of the firm’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $25.59, for a total transaction of $243,105.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,200 shares of company stock valued at $695,518. 5.90% of the stock is currently owned by corporate insiders.
Several equities research analysts have recently weighed in on the stock. Leerink Swann cut shares of Intersect ENT from an “outperform” rating to a “market perform” rating and set a $25.75 price objective for the company. in a research report on Tuesday, May 7th. Northland Securities upgraded shares of Intersect ENT from an “under perform” rating to a “market perform” rating and set a $20.00 price objective for the company in a research report on Wednesday, July 10th. Piper Jaffray Companies cut shares of Intersect ENT from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $30.00 to $17.00 in a research report on Friday. Svb Leerink cut shares of Intersect ENT from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $29.00 in a research report on Tuesday, May 7th. Finally, Zacks Investment Research cut shares of Intersect ENT from a “hold” rating to a “strong sell” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company. Intersect ENT currently has a consensus rating of “Hold” and an average price target of $27.11.
Intersect ENT Company Profile
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
See Also: Return on Equity (ROE)
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.